920TiPErdafitinib compared with vinflunine or docetaxel or...

Annals of Oncology 2018 / 10 Vol. 29; Iss. suppl_8

920TiPErdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study

Loriot, Y, Necchi, A, Park, S H, Huddart, R A, Burgess, E, Zhong, B, Santiago-Walker, A, Little, S, Roccia, T, De Porre, P, Siefker-Radtke, A O
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
29
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy283.129
Date:
October, 2018
File:
PDF, 94 KB
2018
Conversion to is in progress
Conversion to is failed